Cyclosporine and loteprednol combo bests cyclosporine alone in improving dry eye disease

Dry eye has gained its importance as public health problem given its high prevalence, morbidity and cost implications with increased use of gadgets. Although dry eye is common and affects patients’ quality of life, only one medication, cyclosporine 0.05% emulsion, has been approved by the US FDA for its treatment.

A recent study in Clinical Opthalmology aimed to examine the efficacy and tolerability of a combination of cyclosporine 0.1% and loteprednol 0.2% (CsA–LE; Klarity CL) in comparison to commercially available cyclosporine 0.05% (CsA; Restasis) in improving signs and symptoms of dry eye.

The study suggests that on comparison with both the drugs for treatment of dry eyes i.e one with cyclosporine 0.05% alone and one with a combination of cyclosporine 0.1% and loteprednol 0.2%. Both regimens improved ocular surface health, but the combination regimen also improved irregularities of the cornea more effectively than cyclosporine alone.

The researchers conducted a multicenter, prospective, randomized, controlled, open-label study evaluated 60 patients randomized to a single treatment for 4 weeks and evaluated at day 0, day 14, and day 28. Comparison was made of corneal higher-order aberrations (HOAs), dry-eye symptoms (SPEED score), tear-breakup time (TBUT), corneal staining, and ocular hyperemia, as well as tolerability of each medication with the validated COMTOL instrument.